Brought to you by 
Mayne Pharma licenses generics from Pliva
Mar 2005
Executive Summary
Specialty pharmaceuticals company Pliva DD and Mayne Pharma (generics) have entered into an agreement for the development and marketing of Pliva's lead generics programs--erythropoietin (EPO) and granulocyte colony stimulating factor (G-CSF).
Deal Industry
- Biotechnology
-
Pharmaceuticals
- Generic Drugs
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Mayne Pharma licenses generics from Pliva
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice